Scarica l'app Stockscreener
7.09
4.42%
0.30
Dopo l'orario di chiusura:
7.04
-0.05
-0.71%
Arvinas Inc Borsa (ARVN) Ultime notizie
Arvinas, Inc. (NASDAQ:ARVN) Receives $19.76 Consensus PT from Analysts - MarketBeat
Arvinas (NASDAQ:ARVN) Given New $15.00 Price Target at Guggenheim - MarketBeat
Arvinas FY2025 EPS Estimate Lowered by Cantor Fitzgerald - MarketBeat
HC Wainwright Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Metastatic Prostate Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion - Barchart.com
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer - Yahoo Finance
Arvinas (NASDAQ:ARVN) Price Target Cut to $16.00 by Analysts at Wells Fargo & Company - MarketBeat
Q3 Earnings Forecast for Arvinas Issued By Leerink Partnrs - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by XTX Topco Ltd - MarketBeat
Arvinas and Pfizer’s FDA Nod for Cancer Drug - The Globe and Mail
Arvinas, Inc. (NASDAQ:ARVN) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛
Arvinas (NASDAQ:ARVN) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
FDA Accepts Arvinas, Pfizer's Vepdegestrant NDA for Breast Cancer Treatment - AInvest
FDA to Review Pfizer and Arvinas' Breast Cancer Therapy Vepdegestrant by June 5, 2026. - AInvest
Arvinas' Breakthrough in PROTACs: A Catalyst for Valuation Re-Rating in Oncology's New Frontier - AInvest
Arvinas Q2 2025 Earnings: Revenue Down, Clinical Progress & New CEO Announcement - AInvest
Arvinas, Pfizer announce FDA acceptance of vepdegestrant NDA - TipRanks
Arvinas and Pfizer Announce FDA Acceptance of NDA for Vepdegestrant Following Positive Phase 3 VERITAC-2 Trial Results in Advanced Breast Cancer - Quiver Quantitative
Arvinas Announces FDA Acceptance of the New Drug - GlobeNewswire
ARVNArvinas Latest Stock News & Market Updates - Stock Titan
Arvinas Holding Company (ARVN) Gets a Buy from Guggenheim - The Globe and Mail
Arvinas Holding’s Strategic Uncertainties and Partnership Challenges Justify Hold Rating - TipRanks
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $9 to $18 - 富途牛牛
Arvinas (ARVN) Shares Plunge 2.95% to 2025 Low Amid Mixed Clinical Results and Partnership Uncertainty - AInvest
Arvinas 2025 Q2 Earnings Record Net Income Despite Worsening Losses - AInvest
Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug - BioPharma Dive
Arvinas signals CEO transition and extends cash runway into H2 2028 amid vepdeg collaboration changes - MSN
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - Stocktwits
Wedbush Cuts Price Target on Arvinas to $10 From $12, Keeps Neutral Rating - MarketScreener
Arvinas price target raised to $24 from $18 at H.C. Wainwright - TipRanks
Arvinas, Inc. (NASDAQ:ARVN) Q2 2025 Earnings Call Transcript - Insider Monkey
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Guggenheim lowers Arvinas stock price target to $15 on partnership concerns - Investing.com
Insider Sellers Might Regret Selling Arvinas Shares at a Lower Price Than Current Market Value - simplywall.st
Arvinas Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Arvinas Holding Company: Strong Cash Position and Promising Pipeline Justify Buy Rating - TipRanks
Federated Hermes Inc. Purchases 933,183 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Reports Q2 2025 Financials and Drug Developments - TipRanks
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Arvinas Earnings Call: Balancing Progress and Challenges - TipRanks
Arvinas Q2 2025 Earnings Call Transcript - MarketBeat
ARVINAS, INC. SEC 10-Q Report - TradingView
Arvinas Holding Company: Hold Rating Amid Modest Data and Strategic Uncertainties - TipRanks
Transcript : Arvinas, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Arvinas shares fall 16.16% intraday after Q2 revenue drops 71% and net loss widens. - AInvest
Earnings call transcript: Arvinas Q2 2025 results show revenue miss, stock drops - Investing.com Canada
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates - sharewise.com
Arvinas earnings beat by $0.10, revenue fell short of estimates - Investing.com Canada
Arvinas Inc (ARVN) Q2 2025 Earnings: EPS Beats Estimates at -$0. - GuruFocus
Arvinas reports Q2 EPS (84c), consensus (89c) - TipRanks
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):